Log in to your account:
Eli Lilly & Co. (LLY), Boehringer Ingelheim Report CAROLINA Cardiovascular Outcome Trial of Tradjenta Met Primary Endpoint of Non-Inferiority Compared with Glimepiride
February 14, 2019 6:42 AM
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride
February 14, 2019 6:30 AM